The capital will enable Turnstone to advance its platform and pipeline of next-generation oncolytic virus.
July 21, 2021 – FACIT congratulates Turnstone Biologics on completing its $80M USD Series D financing. The capital will enable Turnstone to advance its platform and pipeline of next-generation oncolytic virus and TIL therapeutics in the field of immunotherapy for solid tumours. As evidenced by the participation of both existing and new institutional investors including Versant Ventures, OrbiMed, Sectoral Asset Management, PFM Health Sciences and Point 72, the start-up seeded by FACIT in collaboration with several Ontario research institutes continues to deepen its roots in Canada and grow on both sides of the border.
The Company recently expanded its immune oncology pipeline to include a TIL therapy platform to complement its oncolytic virus therapies. Turnstone’s founding technology platform is the product of a unique collaboration between the Ontario Institute for Cancer Research (OICR), McMaster University, Children’s Hospital of Eastern Ontario, the Ottawa Hospital Research Institute and FACIT.
Read the news release here.
FACIT actively manages our diverse portfolio of Ontario oncology assets (including therapeutics, imaging, diagnostics, and technology platforms) that span all stages of commercialization, from proof-of-concept to clinical development.
With critical seed funding, FACIT makes it possible for Ontario’s best cancer research discoveries to compete globally and reach patients.